The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The known unknown: the challenges of genetic variants of uncertain significance in clinical practice
Open accessAbstract
As genetic testing technology has advanced, allowing scientists to obtain much of the raw data from our DNA, their ability to interpret these data has struggled to keep up. The result is the ubiquity of variants of uncertain significance (VUSs): findings from genetic testing for which the clinical significance is currently unresolved. What to do when these results are found is a problem that has vexed laboratories, clinicians, and patients alike. In this paper, I focus on the issues raised by VUSs in clinical practice, and suggest paths forward. The completion of the Human Genome Project in 2003 was widely heralded as the dawn of a new age of medicine—which, in many ways, it has been, enabling stunning advances in genetic testing and research. However, the ‘book of life’ is written in a language whose alphabet we can read, but whose vocabulary and grammar we do not yet fully understand. As a result, we have the technical ability to report how the ‘words’ of genes are spelled, but still often lack the interpretive ability to say what they mean. Genetic testing is performed clinically for a variety of reasons. Diagnostic testing is done to determine whether a patient with symptoms has a suspected condition, or to determine what condition they have, if their symptoms are non-specific. For example, a child with seizures and dysmorphic features might receive genetic testing to determine whether these features are associated with a known genetic condition. This testing can sometimes provide an explanation, predict recurrence risk, or inform clinical management. Predictive testing or genetic risk assessment is usually performed for people with a family history of a condition for which they have not yet presented symptoms. One example is testing of the BRCA1/2 genes, mutations in which can dramatically increase the risk of breast and ovarian cancer, in people who do not yet have cancer. These types of tests can sometimes lead to clinical interventions such as surgery or enhanced screening, or be useful in life planning. Reproductive testing includes carrier screening, which can inform parents of the risk of having a child affected with a recessive genetic disorder, and prenatal testing, which can determine whether a pregnancy is affected by a genetic condition. These decisions may be used to inform reproductive decision making, including whether and how to become pregnant or whether to continue with a pregnancy, or to help families prepare for the birth of a child with a genetic condition. No matter the context of testing, results generally fall into three categories. ‘Positive’ results usually provide a diagnosis or risk information. ‘Negative’ results, where no relevant genetic variation is found, can sometimes rule out a diagnosis or reduce a risk assessment, or in other cases simply be uninformative. In between positive and negative falls the gray area of the VUS. Every human's DNA sequence—with the usual exception of monozygotic twins—is unique. While some of the difference between individuals is responsible for disease, the majority of it is benign. When DNA testing is performed, the data obtained can be compared to a ‘reference sequence’, and differences from that sequence identified. However, it is not always possible to predict with confidence whether a difference, or variant, found is actually deleterious or just attributable to genetic diversity. Even rare variants in genes known to be associated with disease are now understood to often be benign, contrary to the early expectations of researchers. Variant classification, the process of determining whether a DNA variant causes disease, is in clinical practice generally the province of genetic testing laboratories and relies on multiple lines of evidence. These include whether a variant has been previously seen in individuals with a condition and has not been seen in those without it; what its effect is predicted to be on the protein produced by the gene; and others. While some variants can be confidently predicted using these criteria to either be pathogenic (disease-causing) or benign, in many cases, pieces of evidence are missing or conflict with each other. In these situations, the variant is often classified and reported as a VUS. Recent advances in next-generation sequencing technology that have allowed the rapid and inexpensive sequencing of numerous genes at one time (panel testing), of the regions of the genome that code for proteins (the exome), or the entire genome, have increased the yield of genetic testing and made it more accessible—but have also greatly increased the number of VUSs encountered in clinical practice. Simply put, the more places you look, the more likely you are to find a VUS. The wonderful promise of expanded testing has, in practice, run into the frustrating reality of a greater burden of uncertain results. Another increasing source of VUSs is chromosomal microarray (CMA), a test that looks at larger sections of DNA and can
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Misdiagnoses and the Potential for Health Disparities
Manrai, A. K., Funke, B. H., Rehm, H. L., Olesen, M. S., Maron, B. A., Szolovits, P., Margulies, D. M., Loscalzo, J., & Kohane, I. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmsa1507092 · Cited by 808
Cited by
Drug Repurposing for Rare Diseases
Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.003 · Cited by 269
(2024) · doi:10.1038/s41592-024-02409-0 · Cited by 29
Multiplexed Functional Assessments of MYH7 Variants in Human Cardiomyocytes
Friedman, C. E., Fayer, S., Pendyala, S., Chien, W.-M., Loiben, A., Tran, L., Chao, L. S., McKinstry, A., Ahmed, D., Farris, S. D., et al. (2024) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.123.004377 · Cited by 17
Dilliott, A. A., Kwon, S., Rouleau, G. A., Iqbal, S., & Farhan, S. M. K. (2023) · Brain · doi:10.1093/brain/awad224 · Cited by 8
Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention
Kassem, N., Stout, L. A., Hunter, C., Schneider, B., & Radovich, M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00278 · Cited by 5
Metadata
- Authors
- Hoffman-Andrews, L.
- Venue
- Journal of Law and the Biosciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-01
- Volume
- 4
- Issue
- 3
- Pages
- 648-657
- ISSN
- 2053-9711 (ISSN-L)
- OpenAlex
- W2802380955
- Cited by
- 214
- References
- 1
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. https://app.cochat.ai/papers/10.1093/jlb/lsx038
- The paper
- Hoffman-Andrews, L. (2017). The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. Journal of Law and the Biosciences. https://doi.org/10.1093/jlb/lsx038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.